Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:			
Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.					
				URGENT	
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:					
MALE FEMALE HEIGHT (IN/CI	NEED TO SUBMIT A PHI DISCLO	SURE AUTHORIZATION FORM WITH THIS REQU	JEST WHICH CAN BE FOUND A	T THE	
AUTHORIZED REPRESENTATIVE'S PHON PRESCRIBER INFORMATION	IE NUIVIBER:				
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:			
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
MEDICATION OR MEDICAL DISPENSIN	IG INFORMATION				
MEDICATION NAME:					
DOSE/STRENGTH: FREQUE	NCY:	LENGTH OF	QUANTITY:		
		THERAPY/REFILLS:			
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DAT	ES):				

Continued on next page



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
Z. LIST DIAGNOSES:		1CD-10:		
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION. Clinical Information:	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
, , , , , , , , , , , , , , , , , , , ,	ning the patient has not received therapt Kalydeco in member's history)? □ Yes			
Does the patient have a diagnosis of co				
Does the patient have a CFTR gene mu ☐ Yes ☐ No Test documentation must	station listed within the current FDA pre	escribing information?		
_	nis patient's most recent (baseline) FVC than or equal to 40% predicted? — Yes ., chart notes.			
Is documentation available showing this patient's most recent (baseline) measurements for FEV1 and FEV1 percentage of predicted, obtained within the past 30 days while the patient is NOT receiving treatment with Kalydeco? Yes No Please submit this documentation, e.g., chart notes				
If requesting Kalydeco Granules also a	nswering the following:			
Renewal Therapy You must answer ALL of the following	questions:			
Is this request for initial therapy (meaning the patient has not received therapy with Kalydeco in the past AND there are no paid claims for Kalydeco in member's history)? — Yes — No — No — Yes — No — Person please complete "Initial Therapy" section above.				



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
therapy subject to renewal; those should be submitte	ent assistance program only does not qualify as current
<u>If No</u> , please complete "Initial Therapy" section above.	
Is documentation available which shows the patient's cu Current FEV1 measurements are defined as the most measured within the previous 30 days while the patie Please submit this documentation, such as chart note	recent FEV1 and FEV1 percentage of predicted that were ent is receiving treatment with Kalydeco.
Does the patient have the R117H mutation in the cystic (CFTR) gene? ☐ Yes ☐ No	fibrosis transmembrane conductance regulator
Does the patient have the G551D mutation in the cystic (CFTR) gene? ☐ Yes ☐ No	fibrosis transmembrane conductance regulator
Is the patient's current FEV1 percentage of predicted income than the baseline FEV1 percentage of predicted? Baseline FEV1 percentage of predicted is defined as the was measured while the patient was not receiving the Please submit this documentation, such as chart note.	□ No he most recent FEV1 percentage of predicted that eatment with Kalydeco.
Is the patient's current FEV1 percentage of predicted incomplete than the baseline FEV1 percentage of predicted? Baseline FEV1 percentage of predicted is defined as the was measured while the patient was not receiving tree Please submit this documentation, such as chart note	he most recent FEV1 percentage of predicted that eatment with Kalydeco.
Is the patient's current FEV1 percentage of predicted incomplete than the baseline FEV1 percentage of predicted? Baseline FEV1 percentage of predicted is defined as the was measured while the patient was not receiving tree Please submit this documentation, such as chart note.	he most recent FEV1 percentage of predicted that eatment with Kalydeco.



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
Are there any other comments, diagnoses, symphysician feels is important to this review?	ptoms, medications tried or failed, and/or any other information the
Please note: Not all drugs/diagnosis are covered information is received.	d on all plans. This request may be denied unless all required
•	d is true and accurate to the best of my knowledge. I understand that esignees may perform a routine audit and request the medical the information reported on this form.
Prescriber Signature or Electronic I.D. Verificati	ion: Date:
you are not the intended recipient, you are hereby notified	this transmission contain confidential health information that is legally privileged. If d that any disclosure, copying, distribution, or action taken in reliance on the contents wed this information in error, please notify the sender immediately (via return FAX) nts.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP - 4201
P.O. Box 64811
St. Paul, MN 55164-0811

Prime THERAPEUTICS*